rapidly and remained >400/μl since 1998 whereas his viremia remained only partially controlled (always <1000 copies/ml from 1997 to 2004). He never experienced any opportunistic infection or malignancy. HIV plasma genotyping in 2003 revealed the presence of the D30N and N88D/N mutation, which mediate resistance to nelfinavir and the M184V and T215Y mutation conferring resistance to lamivudine and partial resistance to stavudine. However, because his viral load was always <1000 copies, the patient chose to remain on his HAART regimen. At the time of the first seizure, the patient's CD4+ Tcell count was 794/μl (14%) and his plasma viral load was 281 copies/ml. Magnetic resonance imaging (MRI) revealed diffuse frontal and temporal white matter T2-hyperintensities. Contrast-enhanced studies were negative. These findings were consistent with HIV-1-associated encephalopathy and not suggestive for opportunistic infection. The patient remained otherwise asymptomatic and did not show any signs of cognitive impairment. Twelve months later his HAART regimen was changed for more convenient dosing to once-daily ritonavir/atazanavir,
The authors describe a patient with known human immunodeficiency virus (HIV)-1 infection who presented with two generalized seizures and was found to have extensive white matter disease and a left/bilateral temporo-occipital focal slowing on electroencephalography (EEG). There were no magnetic resonance imaging (MRI) or cerebrospinal fluid (CSF) indications for opportunistic infection. Plasma viremia was controlled, whereas viral replication was uncontrolled in CSF. CSF-specific genotype-guided adaptation of the antiretroviral therapy in order to optimize central nervous system (CNS) penetration resulted in clinical improvement and normalization of MRI and EEG. Our case report illustrates the importance of individualized antiretroviral therapy in HIV infected patients with neurological complications. Journal of
14, 78-84.
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Case report
In August 2003, a 40-year-old man with longstanding human immunodeficiency virus (HIV)-1 infection presented with a first-generalized tonic-clonic seizure. HIV-infection was known since 1987 and the patient was enrolled in a methadone program since 1986. He took zidovudine monotherapy from 1993 to1997, and was on highly active antiretroviral therapy (HAART) since 1997. From 1997 to 2003 he was treated with lamivudine and stavudine complemented with indinavir from 1997 to 1999, and nelfinavir from 1999 to 2003 (Figure 1) . He also had a brief exposure to efavirenz, which was stopped because of neuropsychiatric side effects. The patient's nadir CD4+ T-cell count was 166/μl (11%) before HAART initiation; but his CD4+ T cells rose rapidly and remained >400/μl since 1998 whereas his viremia remained only partially controlled (always <1000 copies/ml from 1997 to 2004). He never experienced any opportunistic infection or malignancy. HIV plasma genotyping in 2003 revealed the presence of the D30N and N88D/N mutation, which mediate resistance to nelfinavir and the M184V and T215Y mutation conferring resistance to lamivudine and partial resistance to stavudine. However, because his viral load was always <1000 copies, the patient chose to remain on his HAART regimen. At the time of the first seizure, the patient's CD4+ Tcell count was 794/μl (14%) and his plasma viral load was 281 copies/ml. Magnetic resonance imaging (MRI) revealed diffuse frontal and temporal white matter T2-hyperintensities. Contrast-enhanced studies were negative. These findings were consistent with HIV-1-associated encephalopathy and not suggestive for opportunistic infection. The patient remained otherwise asymptomatic and did not show any signs of cognitive impairment. Twelve months later his HAART regimen was changed for more convenient dosing to once-daily ritonavir/atazanavir, Figure 1 Chronology of antiretroviral therapy with quantification of CNS penetration. VL: viral load. AZT = zidovudine; d4T = stavudine; 3TC = lamivudine; IDV = indinvavir; NFV = nelfinavir; rATV = ritonavir-boosted atazanavir; TDF = tenofovir; ddI = didanosine; LPV = ritonavir-boosted lopinavir; NVP = nevirapine.
with didanosine and tenofovir. His plasma viral load now became undetectable (<40 copies/ml). Two months later he experienced another generalized seizure, which prompted a neurological evaluation, which was unremarkable without signs of cognitive or memory impairment. Repeat MRI showed moderate progression of the diffuse white matter disease ( Figure 2A ). Electroencephalography (EEG) revealed subtle background alterations with a bilateral temporo-occipital focal slowing ( Figure 3A ).
Cerebrospinal fluid (CSF) analysis revealed pleiocytosis (32 × 10 6 /L), elevated protein (917 mg/L), and immunoglobulin G (IgG) (527 mg/L) and oligoclonal bands. Serologic assays for borreliae, syphilis, herpes simplex virus, and varicella zoster virus (VZV) were negative as well as polymerase chain reaction (PCR) assays for Toxoplasma gondii, JC virus, Epstein Barr virus, cytomegalovirus, and VZV. The cerebrospinal fluid (CSF) HIV viral load was 8896 copies/ml, whereas plasma viremia remained undetectable (<40 copies/ml). Genotyping of the CSF virus revealed thymidine-analogue mutations M41L and T215Y, conferring intermediate resistance to zidovudine and low-level resistance to didanosine and tenofovir, the A98G polymorphism on the reverse transcriptase gene, and L63P polymorphism on the protease gene. Attempting to adapt the patient's HAART for higher efficacy against the HIV quasispecies in central nervous system (CNS) and for optimal CSF penetration, his regimen was now changed to nevirapine, zidovudine and lamivudine, and lopinavir/ritonavir. The patient was also started on antiepileptic therapy with levetiracetam, which he discontinued after 4 months. He has remained seizure free for almost 3 years to date and still shows no sign of cognitive impairment. A followup MRI demonstrated normalization of previous T2-hyperintensities with some widening of the lateral ventricles probably indicating resolution of edema, possibly unmasking some degree of subcortical brain atrophy ( Figure 2B ). A follow-up EEG after 19 months had also almost normalized ( Figure 3B ). CSF analysis 12 months after switching to CNS-adapted HAART showed resolution of pleiocytosis and reduction in total protein (679 mg/L) and IgG (345 mg/L). The CSF HIV viral load was now undetectable (<50 copies/ml).
Discussion
Epileptic seizures are a frequent event in HIVinfected patients. Before the ART-era, their annual incidence was estimated up to 11% and in one study even up to 17%, whereas a reduced frequency with a prevalence of up to 6% was reported in the ARTera (Dore et al, 1999; Kellinghaus et al, 2007; Levy and Bredesen, 1988; Pascual-Sedano et al, 1999) . In almost 50% of cases, no causal opportunistic disease was identified, suggesting a HIV-related pathogenesis (Langford et al, 2003) . The differential diagnosis in HIV-infected patients with seizures comprises infections such as toxoplasmosis, cryptococcal or tuberculous meningitis, and progressive multifocal leukencephalopathy (PML) (Price, 1996) . Furthermore, CNS lymphoma and drugs used for treatment of the HIV infection and metabolic alterations such as renal or hepatic failure may predispose for seizures (Barton et al, 1992; D'Silva et al, 1995) . As the second seizure occurred in our patient after changing the antiretroviral therapy, an immune reconstitution syndrome might have also triggered it. However, no increase of lymphocyte counts was detected after modification of the therapy and the MRI showed no contrast-medium enhancement, both of which argue against the possibility of seizures caused by a immune reconstitution inflammatory syndrome in the CNS (Venkataramana et al, 2006) .
We therefore considered the seizures as secondary manifestation of the HIV infection in CNS and initiated an antiepileptic treatment with levetiracetam. Levetiracetam has been reported to be efficacious in HIV-positive patients with HAART treatment (Liedtke et al, 2004) . It undergoes minor metabolism by plasma hydrolases, but not by the liver, as it does not interact with the hepatic cytochrome P450 (CYP450) enzyme function by which most protease inhibitors and non-nucleoside reverse transcriptase inhibitors are metabolized. Interactions of antiretroviral agents and the well-known antiepileptic drugs carbamazepine, phenytoin, and phenobarbital have been described in HAART-treated patients, especially when protease inhibitors are given (Liedtke et al, 2004; Bates et al, 2006) . Valproic acid has been discussed to have a potential neuroprotective effect in HIV-associated cognitive impairment (Dou et al, 2003; Schifitto et al, 2006) . It is metabolized by the hepatic CYP450 system (mainly the 2C9 isoform) and is conjugated by the uridyl-glucuronyl transferase, but has been reported to be save when given in combination with the non-nucleoside reverse transcriptase inhibitor efavirenz and the protease inhibitor lopinavir (DiCenzo et al, 2004) . In contrast, valproic acid acts as a modest inhibitor of several CYP450 isoforms and might thereby prolong the elimination half-time of antiretroviral drugs metabolized by this system. Conflicting results regarding a positive effect of valproic acid on the eradication of latent virus reservoirs have been reported (Lehrman et al, 2005; Siliciano et al, 2007) . Table 1a comprehensively summarizes the properties of antiepileptic drugs for the treatment of HIV-related seizures with special emphasis given to their potential of interaction with antiretroviral drugs. The hepatic CYP450 metabolism of antiretroviral drugs and their influence on this enzyme system is presented in Table 1b , which also displays the interaction profile of antiretroviral drug with the currently used antiepileptic drugs.
In HIV-infected patients, imaging studies after seizures have often been reported as negative with respect to structural alterations (McArthur et al, 2005) . Clonal expansion of HIV quasispecies in the CNS may account for distinct manifestation of CNS disease and HIV replication in the CNS may be independent from other body compartments as drug mutations distinct from plasma virus can be detected in CSF (Antinori et al, 2005; Temesgen et al, 2006) . Furthermore, antiretroviral drug penetration into the CNS varies greatly between different drugs and shows significant interindividual variability (Antinori et al, 2005; McGee et al, 2006) . Our patient had been on partially suppressive HAART for 7 years, the last 5 of which he was taking a regimen with overall suboptimal CNS penetration (nelfinavir/stavudine/lamivudine). Even though he had achieved complete suppression of plasma viremia at time of his second seizure after switching his antiretrovirals to a more "modern" regimen, lumbar puncture revealed poorly controlled HIV replication in the CNS. Genotypic resistance testing of the HIV variant isolated from the CSF virus revealed a resistance pattern distinct from plasma virus. We decided to adapt the patient's HAART to specifically target CSF variants, using drugs with optimal CSF/CNS penetration (nevirapine, zidovudine) or proven efficacy in reducing HIV CNS replication (lopinavir/ritonavir), accounting for results of genotypic resistance testing of the patient's HIV CSF variant (Antinori et al, 2005; Thomas, 2004; Van Den Brande, 2006) . This was followed by resolution of white matter abnormality on MRI and normalization of EEG. Follow-up CSF studies demonstrated resolved CSF pleiocytosis and undetectable CSF viral load.
This case report highlights the importance of individualizing HAART in patients with HIV associated neurological disease. It also underlines the potential usefulness of measuring CSF viral load with the option of genotyping distinct HIV variants. This diagnostic approach should be considered in all HIVpositive patients who undergo lumbar puncture for CNS disease. It may be of particular interest in patients taking HAART with suboptimal or poor CSF penetration. 
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